Dr. Reddy';s Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market

Rhea-AI Summary

Dr. Reddy’s Laboratories has launched Posaconazole Delayed-Release Tablets, a generic equivalent to NOXAFIL®, approved by the U.S. FDA. The product is now available in 100 mg strength, with U.S. sales of NOXAFIL® reaching approximately $140.8 million over the past year. This move supports Dr. Reddy’s commitment to providing affordable, innovative medicines. The tablets come in a bottle count of 60.

Positive

• Launch of Posaconazole Delayed-Release Tablets enhances product portfolio.
• Generic version targets a market with $140.8 million in annual sales.

Negative

• None.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, the therapeutic generic equivalent to NOXAFIL® (posaconazole) Delayed-Release Tablets, 100 mg approved by the U.S. Food and Drug Administration (USFDA).

The NOXAFIL® brand and generic had U.S. sales of approximately $140.8 million MAT for the most recent twelve months ending in February 2022 according to IQVIA*.

Dr. Reddy’s Posaconazole Delayed-Release Tablets are available in 100 mg strength in bottle count sizes of 60.

Please click here to see the full prescribing information along with the approved indication for Dr. Reddy’s Posaconazole Tablets, 100 mg: https://www.drreddys.com//pi/posaconazole-dr-tabs-100mg-us_outsert-v_4-150088755.pdf

*IQVIA Retail and Non-Retail MAT February 2022.

RDY-0422-404

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005931/en/

INVESTOR RELATIONS

AMIT AGARWAL

AMITA@DRREDDYS.COM

MEDIA RELATIONS

USHA IYER

USHAIYER@DRREDDYS.COM

Source: Dr. Reddy’s Laboratories Ltd.

FAQ

What new product has Dr. Reddy's launched related to the stock symbol RDY?

Dr. Reddy's has launched Posaconazole Delayed-Release Tablets, a generic equivalent to NOXAFIL®.

How much did the brand NOXAFIL® earn in sales before Dr. Reddy's release?

NOXAFIL® had U.S. sales of approximately $140.8 million over the last twelve months.

What is the approval status of Dr. Reddy's Posaconazole Tablets?

Dr. Reddy's Posaconazole Tablets have been approved by the U.S. FDA.

What strength and size are the newly launched Posaconazole tablets?

The tablets are available in 100 mg strength and come in a bottle count size of 60.